16. The compound of any of claims 1 to 15, having a Btk-inhibiting activity corresponding to an IC50 of 10 uM or less in a Btk Kinase Assay.

17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any of claims 1 to 15 in unit dosage form and one or more pharmaceutically acceptable carriers.

18. A combination comprising a therapeutically effective amount of a compound of any of claims 1 to 15 and a different agent therapeutically active against an autoimmune and/or inflammatory disease or cancer.

19. A compound for use in treating a disease associated with undesirable Btk activity, which comprises administering to a person in need thereof an effective amount of a compound of any of claims 1-15, wherein the disease is an allergic disease, an autoimmune disease, an inflammatory disease, or cancer.

20. The compound of claim 19 wherein the disease is a B-cell proliferative disorder, selected from chronic lymphocytic lymphoma, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia.